

Registered number: 07372866

NARROWCLIFF MEDICAL SERVICES LIMITED

UNAUDITED

DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020



NARROWCLIFF MEDICAL SERVICES LIMITED

COMPANY INFORMATION

Directors	Miss H Patel Mr J C Patel
Company secretary	Mr A R Patel
Registered number	07372866
Registered office	2 Peterwood Way Croydon Surrey CR0 4UQ

NARROWCLIFF MEDICAL SERVICES LIMITED

CONTENTS

	Page
Directors' Report	1
<i>Profit and Loss Account</i>	2
Statement of Comprehensive Income	2
Balance Sheet	3
Statement of Changes in Equity	4
Notes to the Financial Statements	5 - 11

NARROWCLIFF MEDICAL SERVICES LIMITED

**DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2020**

The directors present their report and the financial statements for the year ended 31 March 2020.

Principal activity

The principal activity of the company during the year was that of a holding company.

Directors

The directors who served during the year were:

Miss H Patel
Mr J C Patel

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.



Mr J C Patel
Director

Date: 11 February 2021

2 Peterwood Way
Croydon
Surrey
CR0 4UQ

NARROWCLIFF MEDICAL SERVICES LIMITED

**PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2020**

	Note	2020 £	2019 £
Administrative expenses		1,898	(668)
Operating profit/(loss)		1,898	(668)
Income from shares in group undertakings		-	560,367
Amounts written off investments		-	(1,906,809)
Interest receivable and similar income		5	4
Profit/(loss) before tax		1,903	(1,347,106)
Tax on profit/(loss)	3	(362)	-
Profit/(loss) for the financial year		1,541	(1,347,106)

**STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2020**

	Note	2020 £	2019 £
Profit/(loss) for the financial year		1,541	(1,347,106)
Other comprehensive income		-	-
Total comprehensive income for the year		1,541	(1,347,106)

There were no recognised gains and losses for 2020 or 2019 other than those included in the profit and loss account.

The notes on pages 5 to 11 form part of these financial statements.

NARROWCLIFF MEDICAL SERVICES LIMITED
REGISTERED NUMBER:07372866

BALANCE SHEET
AS AT 31 MARCH 2020

	Note	2020 £	2019 £
Fixed assets			
Investments	4	1,800	1,800
		<u>1,800</u>	<u>1,800</u>
Current assets			
Debtors: amounts falling due within one year	5	596,231	596,231
Cash at bank and in hand	6	-	4,152
		<u>596,231</u>	<u>600,383</u>
Creditors: amounts falling due within one year	7	(1,960,124)	(1,965,817)
Net current liabilities		<u>(1,363,893)</u>	<u>(1,365,434)</u>
Total assets less current liabilities		<u>(1,362,093)</u>	<u>(1,363,634)</u>
Net liabilities		<u>(1,362,093)</u>	<u>(1,363,634)</u>
Capital and reserves			
Called up share capital	9	5	5
Profit and loss account	10	(1,362,098)	(1,363,639)
		<u>(1,362,093)</u>	<u>(1,363,634)</u>


The directors consider that the Company is entitled to exemption from audit under section 479A of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



Mr J C Patel

Director

Date: 11 February 2021

The notes on pages 5 to 11 form part of these financial statements.

NARROWCLIFF MEDICAL SERVICES LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2020**

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2019	5	(1,363,639)	(1,363,634)
Comprehensive income for the year			
Profit for the year	-	1,541	1,541
Total comprehensive income for the year	-	1,541	1,541
At 31 March 2020	5	(1,362,098)	(1,362,093)

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2019**

	Called up share capital	Profit and loss account	Total equity
	£	£	£
At 1 April 2018	5	(16,533)	(16,528)
Comprehensive income for the year			
Loss for the year	-	(1,347,106)	(1,347,106)
Total comprehensive income for the year	-	(1,347,106)	(1,347,106)
At 31 March 2019	5	(1,363,639)	(1,363,634)

The notes on pages 5 to 11 form part of these financial statements.

NARROWCLIFF MEDICAL SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

1. General information

Narrowcliff Medical Services Limited (the "Company") is a private company limited by shares and incorporated, domiciled and registered in England in the United Kingdom. The address of the registered office is given on company information page. The nature of the company's operations and its principal activities are set out in the director's report on page 1.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The functional currency of Narrowcliff Medical Services Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates. The financial statements are also presented in pounds sterling and rounded to nearest £.

The following principal accounting policies have been applied:

2.2 Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
- the requirements of Section 26 Share-based Payment paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
- the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Day Lewis Plc as at 31 March 2020 and these financial statements may be obtained from 2 Peterwood Way, Croydon, Surrey, CR0 4UQ.

2.3 Exemption from preparing consolidated financial statements

The Company is a parent Company that is also a subsidiary included in the consolidated financial statements of its immediate parent undertaking established under the law of an EEA state and is therefore exempt from the requirement to prepare consolidated financial statements under section 400 of the Companies Act 2006.

2.4 Going concern

As the directors do not intend to acquire a replacement trade, the directors have not prepared the financial statements on a going concern basis.

NARROWCLIFF MEDICAL SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

2. Accounting policies (continued)

2.5 Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.6 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

2.7 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.8 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.9 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.10 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.11 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the

NARROWCLIFF MEDICAL SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

2. Accounting policies (continued)

2.11 Financial instruments (continued)

case of a small company, or a public benefit entity concessionary loan.

Investments in non-derivative instruments that are equity to the issuer are measured:

- at fair value with changes recognised in the Profit and Loss Account if the shares are publicly traded or their fair value can otherwise be measured reliably;
- at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

NARROWCLIFF MEDICAL SERVICES LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020**

3. Taxation

	2020 £	2019 £
Corporation tax		
Current tax on profits for the year	362	-
Total current tax	<u>362</u>	<u>-</u>
Deferred tax	-	-
Total deferred tax	<u>-</u>	<u>-</u>
Taxation on profit on ordinary activities	<u>362</u>	<u>-</u>

Factors affecting tax charge for the year

The tax assessed for the year is the same as (2019 - *lower than*) the standard rate of corporation tax in the UK of 19% (2019 - 19%). The differences are explained below:

	2020 £	2019 £
Profit/(loss) on ordinary activities before tax	<u>1,903</u>	<u>(1,347,106)</u>
Profit/(loss) on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2019 - 19%)	362	(255,950)
Effects of:		
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	-	362,294
Non-taxable income	-	(106,470)
Group relief	-	126
Total tax charge for the year	<u>362</u>	<u>-</u>

Factors that may affect future tax charges

At Budget 2020, the government announced that the Corporation Tax main rate for the years starting 01 April 2020 and 2021 would remain at 19%.

NARROWCLIFF MEDICAL SERVICES LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020**

4. Fixed asset investments

	Investments in subsidiary companies £
Cost	
At 1 April 2019	1,800
At 31 March 2020	<u>1,800</u>

Subsidiary undertaking

The following was a subsidiary undertaking of the Company:

Name	Registered office	Principal activity	Class of shares	Holding
S.Kaye & Son Limited	2 Peterwood Way, Croydon, Surrey, CR0 4UQ	Dormant	Ordinary shares £1 each	100%

5. Debtors

	2020 £	2019 £
Amounts owed by group undertakings	560,367	560,367
Other debtors	35,864	35,864
	<u>596,231</u>	<u>596,231</u>

6. Cash and cash equivalents

	2020 £	2019 £
Cash at bank and in hand	-	4,152
	<u>-</u>	<u>4,152</u>

NARROWCLIFF MEDICAL SERVICES LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020**

7. Creditors: Amounts falling due within one year

	2020 £	2019 £
Amounts owed to group undertakings	1,959,754	1,965,809
Corporation tax	370	8
	<u>1,960,124</u>	<u>1,965,817</u>

8. Financial instruments

	2020 £	2019 £
Financial assets		
Financial assets measured at fair value	-	4,152
Financial assets measured at amortised cost	596,231	596,231
	<u>596,231</u>	<u>600,383</u>
Financial liabilities		
Financial liabilities measured at amortised cost	<u>(1,959,754)</u>	<u>(1,965,808)</u>

9. Share capital

	2020 £	2019 £
Allotted, called up and fully paid		
40 (2019 - 40) Ordinary shares of £0.125 each	<u>5</u>	<u>5</u>

10. Reserves

Profit and loss account

The profit and loss reserve represents cumulative profits or losses, including dividends paid and other adjustments.

11. Contingent liabilities

The company is a party to intra-group cross guarantees in respect of bank borrowing within the group.

- Unlimited inter-company guarantees supported by legal charges over various properties and other respective associated assets.

NARROWCLIFF MEDICAL SERVICES LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2020**

12. Related party transactions

The company owed £1,959,754 (2019: £1,965,809) to Day Lewis plc, the parent company of the company.

13. Controlling party

The company's immediate parent company is Day Lewis plc, a company registered in England and Wales. It prepares group accounts which are available at Day Lewis House, 2 Peterwood Way, Croydon, Surrey, CR0 4UQ.

The ultimate parent company is Day Lewis Holdings Limited, a company registered in Cyprus and controlled by the KCTP Will Trust.

Copies of the ultimate parent and of its group financial statements are not publicly available.